Live Breaking News & Updates on ப்ரிடிக்ஶந் அமைப்பு

Stay updated with breaking news from ப்ரிடிக்ஶந் அமைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene's Innovative Individualized Immunotherapy


(Paris:TNG)
(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s
myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient.
This innovative approach combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers.
THE FIRST PATIENT HAS BEEN DOSED AT THE IUCT ONCOPOLE IN TOULOUSE, France, ....

United States , France General , United Kingdom , Alexandra Martinez , Christian Ottensmeier , Christophe Le Tourneau , Jean Pierre Delord , Transgene Euronext , Institut Curie , Institut Claudius Regaud , Head Of The Department Drug Development , Claudius Regaud Institute , Clatterbridge Cancer Centre , University Of Liverpool , Health Campus , Toulouse Cancer Research Center , Head Of Surgical Department , Toulouse University Hospital Center , Euronext Paris , Artificial Intelligence , General Manager , Prediction System , Good Manufacturing Practices , Consultant Medical Oncologist , Drug Development , Matthew Block ,

First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgenes Innovative Individualized Immunotherapy


Transgene (Paris:TNG)
(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s
myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient.
This innovative approach combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers.
THE FIRST PATIENT HAS BEEN DOSED AT THE IUCT ONCOPOLE IN TOULOUSE, France, ....

United States , France General , United Kingdom , Lucie Larguier , Jean Pierre Delord , Sylvie Berrebi , Institut Claudius Regaud , Alexandra Martinez , Christian Ottensmeier , Christophe Le Tourneau , Transgene Euronext , Institut Curie , Citigate Dewe Rogerson , Head Of The Department Drug Development , Claudius Regaud Institute , Clatterbridge Cancer Centre , University Of Liverpool , Health Campus , Toulouse Cancer Research Center , Corporate Communications , Head Of Surgical Department , Toulouse University Hospital Center , Regulatory News , Euronext Paris , Artificial Intelligence , General Manager ,